OXiGENE presents updated data from ZYBRESTAT Phase 2 study in NSCLC at 2010 ASCO

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ (CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). The updated analysis showed that meaningful improvements were observed in response rate, progression-free survival and overall survival rates in the study arm (ZYBRESTAT combined with bevacizumab and carboplatin/paclitaxel chemotherapy) as compared with the control arm (bevacizumab and chemotherapy) of the trial. The combination regimen including ZYBRESTAT was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study.

The data were presented in a poster titled, "Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin, paclitaxel and bevacizumab in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial," by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles and primary investigator in the study.

"The data gathered to date from the FALCON study are highly encouraging as they demonstrate improvement over the standard of care for this challenging and aggressive disease," commented Dr. Garon. "This initial trend is exciting, and if maintained as the data matures, these results strongly suggest that ZYBRESTAT should be evaluated further in a Phase 3 study in non-small cell lung cancer."

"We believe that these promising data continue to build upon the growing body of evidence demonstrating that ZYBRESTAT can yield clinical benefit without increased toxicity when added to existing mainstay cancer therapies," commented Peter Langecker, M.D., Chief Executive Officer at OXiGENE. "This study is the first trial to investigate the combined use of a vascular disrupting agent with an anti-angiogenic therapy at full strength. Anti-angiogenic agents represented an important breakthrough when combined with conventional chemotherapy in multiple tumor types, and have since become the standard by which other therapies are measured. We believe that the addition of the VDA ZYBRESTAT represents the next key step in treating patients with cancer."